Current Headlines

  1. Enigma Biomedical USA Announces FDA Acceptance Of New Drug Application For Florquinitau F-18 (MK-6240), A Tau PET Alzheimer's Disease Radiodiagnostic 10/28/2025

    Enigma Biomedical USA (EB USA) today announced that the Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for MK-6240 (florquinitau F-18), their Tau Positron Emission Tomography (PET) Alzheimer’s disease radiodiaganostic.

  2. Lantheus Announces FDA Acceptance Of New Drug Application For MK-6240, A PET Imaging Agent Targeting Tau In Alzheimer's Disease 10/28/2025

    Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for MK-6240, the company’s investigational F18-labeled tau-targeted Positron Emission Tomography (PET) imaging agent for the detection of tau neurofibrillary tangle (NFT) pathology in patients with cognitive impairment being evaluated for Alzheimer’s disease. MK-6240 previously received Fast Track designation from the FDA for its potential to address an unmet medical need in Alzheimer’s disease diagnostics.

  3. Genesis Molecular AI Unveils Pearl, A Field-Leading Foundation Model That Achieves Unprecedented Performance In Drug-Protein Structure Prediction 10/28/2025

    Genesis Molecular AI, the company pioneering the world’s leading molecular AI models for drug design and development, today announced Pearl, a generative foundation model for biomolecular structure prediction trained with novel architecture, training methodology, and large-scale synthetic data.

  4. Merck Partners With Promega To Advance 3-D Cell Drug Discovery Technologies 10/28/2025

    Merck, a leading science and technology company, has entered into a partnership with Promega Corporation, a global life science solutions and service leader based in Madison, Wisconsin in the US, to co-develop novel technologies that advance drug screening and discovery.

  5. MicrobiotiX Receives IND Approval For Novel Bacteriophage Drug MP101 10/27/2025

    MicrobiotiX Co., Ltd. (CEO Dongeun Yong), a company specializing in the development of novel bacteriophage therapeutics, announced on October 27 that it received Investigational New Drug (IND) approval from the Ministry of Food and Drug Safety (MFDS) on October 21 for MP101, its investigational bacteriophage therapy for patients with acute pneumonia.

  6. Research Breakthroughs Lead To Potential New Parkinson's Drug 10/27/2025

    AbbVie Pharmaceuticals has submitted a New Drug Application (NDA) to the federal Food and Drug Administration for the first novel drug treatment for Parkinson’s disease in more than half a century.

  7. SciSparc Targets Quantum-Powered 3D Protein Modeling Technology To Revolutionize AI Drug Discovery 10/23/2025

    SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, recently announced that on September 16, 2025 the board of directors resolved to initiate the launch of an innovative initiative to advance 3D protein modeling using quantum computing technology (the “Initiative”).

  8. Alloy Therapeutics Announces Acquisition Of Spannerwerks, A Leading Provider Of Drug Development Consulting Services 10/23/2025

    Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced the acquisition of Spannerwerks, LLC, a Seattle-based professional services firm that guides biopharmaceutical companies on the development and launch of new products.

  9. Cambrex Unveils $120 Million Investment To Expand API Manufacturing And Strengthen U.S. Drug Supply Resilience 10/22/2025

    Cambrex, a leading global CDMO, is addressing increased demand for API development and manufacturing and accelerating the company’s leadership role in the fast-growing peptide therapeutics market.

  10. Invenra Inc. And Xcellon Biologics Announce Collaboration To Advance Bispecific And Trispecific Antibody-Drug Conjugate (ADC) Development 10/22/2025

    Invenra Inc., a U.S.-based biotechnology company pioneering multispecific antibody platform technologies, and Xcellon Biologics, a wholly owned subsidiary of Linden Lake Labs and a U.S.-based contract development and manufacturing organization (CDMO) specializing in antibody–drug conjugates (ADCs) and complex biologics, today announced a strategic collaboration to advance the development of multispecific ADCs.